Ironwood Pharmaceuticals (IRWD) Research & Development (2010 - 2026)

Ironwood Pharmaceuticals has disclosed Research & Development across 17 years of filings, most recently posting $22.4 million for Q2 2026.

• In Q2 2026, Research & Development fell 4.07% year-over-year to $22.4 million; the TTM figure through Jun 2026 stood at $88.7 million (down 16.35% YoY), while the FY2025 annual figure was $95.1 million, down 14.62% from the prior year.
• Research & Development came in at $22.4 million for Q2 2026 at Ironwood Pharmaceuticals, up from $21.9 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $35.7 million in Q4 2023 to a low of $10.4 million in Q4 2022.
• Average Research & Development over 5 years is $22.8 million, with a median of $22.9 million recorded in 2025.
• Year-over-year, Research & Development tumbled 67.2% in 2022 and jumped 241.53% in 2023.
• Over 5 years, Research & Development stood at $10.4 million in 2022, then jumped by 241.53% to $35.7 million in 2023, then decreased by 28.83% to $25.4 million in 2024, then decreased by 13.89% to $21.9 million in 2025, then advanced by 2.55% to $22.4 million in 2026.
• Per Business Quant data, the three most recent Research & Development figures were $22.4 million in Q2 2026, $21.9 million in Q1 2026, and $21.9 million in Q4 2025.